BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations

Hims & Hers Health (NYSE:HIMS) absorbed different expert downgrade. Bank of America chopped its terms nonsubjective connected Hims & Hers banal to $30 from $32, portion keeping a Neutral rating. The steadfast called the caller results "a mixed quarter" and argued that the barroom needs to travel down earlier HIMS banal tin enactment again.

The terms people chopped follows a Q1 2026 study that missed connected some the apical and bottommost lines. Hims & Hers posted gross of $608.1 cardinal against a statement of $616.85 million, and reported diluted EPS of -$0.40 versus the Street's $0.03 expectation.

For prudent investors, Bank of America's Hims & Hers downgrade signals a classical high-expectations reset alternatively than a cardinal displacement successful the thesis. HIMS banal traded astatine $23.85 intraday, good beneath the chopped target.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Hims & Hers wasn't 1 of them. Get them present FREE.

The Analyst's Case

Bank of America's halfway statement is straightforward: Street assumptions are excessively precocious successful the adjacent term, and statement models request to recalibrate. The steadfast believes the barroom indispensable reset earlier Hims & Hers banal tin find traction.

That presumption sits successful the mediate of a divided Street. JPMorgan trimmed its HIMS banal terms people to $33 from $35 portion keeping an Overweight rating, and Canaccord really raised its people to $32 from $30 with a Buy rating. The dispersion reflects genuine disagreement astir however to worth Hims & Hers aft its strategical pivot.

Company Snapshot

Hims & Hers operates a multi-specialty telehealth level connecting consumers with licensed clinicians crossed brands including Hims, Hers, ZAVA, and Labs. The institution finished Q1 2026 with astir 2.6 cardinal subscribers, up 9% twelvemonth implicit year.